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Key Points
• Triplet lenalidomide-based
regimens did not induce any
advantage over doublet
lenalidomide-based regimens
in elderly myeloma patients.
Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple
myeloma patients. We randomly assigned 662 patients who were age ‡65 years or
transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide
(MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus low-
dose dexamethasone (Rd). The primary end point was progression-free survival (PFS) in
triplet (MPR and CPR) vs doublet (Rd) lenalidomide-containing regimens. After a median
follow-upof 39months, themedianPFSwas22months for the triplet combinationsand21
months for the doublet (P 5 .284). The median overall survival (OS) was not reached in
either arms, and the 4-year OS was 67% for the triplet and 58% for the doublet arms (P5 .709). By considering the 3 treatment arms
separately, no difference in outcome was detected amongMPR, CPR, and Rd. The most common grade ‡3 toxicity was neutropenia:
64% in MPR, 29% in CPR, and 25% in Rd patients (P < .0001). Grade ‡3 nonhematologic toxicities were similar among arms and were
mainly infections (6.5% to 11%), constitutional (3.5% to 9.5%), and cardiac (4.5% to 6%), with no difference among the arms. In
conclusion, in theoverall population, thealkylator-containing tripletsMPRandCPRwerenot superior to thealkylator-freedoubletRd,
whichwas associated with lower toxicity. This study was registered at www.clinicaltrials.gov as #NCT01093196. (Blood. 2016;127(9):
1102-1108)
Introduction
Multiple myeloma (MM) is the second most frequent hematologic
cancer, with a median age at diagnosis of ;70 years.1 MM is still an
incurable disease, but novel agents, such as the proteasome inhibitor
bortezomib and immunomodulatory drugs thalidomide and lenalido-
mide have considerably improved progression-free survival (PFS) and
overall survival (OS).2-6 InEurope,melphalan-prednisone-thalidomide
(MPT) and melphalan-prednisone-bortezomib (VMP) are considered
the standards of care for MM patients older than age 65 years or not
eligible for autologous stem cell transplantation.2,3,7-13 Recently, two
large phase 3 trials have shown the superiority of lenalidomide-
containing regimens over the standard treatments approved for
elderly patients with newly diagnosed MM.14,15 The MM-015
trial showed that combined melphalan-prednisone-lenalidomide
(MPR) followed by maintenance with lenalidomide (MPR-R)
signiﬁcantly prolonged PFS (31 months) compared with
melphalan-prednisone (13 months; P , .001) or MPR without
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maintenance (14months;P, .001). Themajor beneﬁt was observed
in patients age 65 to 75 years (P 5 .001 for treatment-by-age
interaction).14 The FIRST trial showed that lenalidomide plus low-
dose dexamethasone (Rd) given until disease progression was
associated with a signiﬁcant improvement in PFS (25.5 months)
when comparedwithmelphalan-prednisone-thalidomide (21.2months)
or Rd (20.7 months) for a ﬁxed period of 18 months (hazard ratio
[HR] for the risk of progression or death was 0.72 for continuous
Rd vsMPT and 0.70 for continuousRd vs 18months of Rd;P, .001
for both comparisons).The advantage ofRd given continuously or for
a ﬁxed period was evident in patients older than or younger than age
75 years.15
To date, a formal comparison between an alkylator-containing
triplet regimen vs an alkylator-free doublet regimen, both including
lenalidomide, has not yet been performed. In this phase 3 trial, we
compared a triplet lenalidomide-containing regimen (MPR or
cyclophosphamide-prednisone-lenalidomide [CPR]) with a doublet
lenalidomide-containing regimen (Rd) to evaluate which was the
best drug to combine with lenalidomide (alkylating agents or
steroids). The primary end point was PFS with the triplet vs the
doublet lenalidomide-containing regimens.
Patients and methods
Study patients
Patients with newly diagnosed MM who were ineligible for high-dose therapy
plus stem cell transplantation because of age ($65 years) or coexisting
comorbidities could be enrolled. Inclusion criteria were measurable disease and
Karnofsky performance status$60%. Patients agreed to use contraception, and
women of childbearing age had a pregnancy test before enrollment. Exclusion
criteria included renal impairment (creatinine level,30 mL/min), uncontrolled
or severe cardiovascular disease, and other malignancies within the past 3 years.
The study was approved by the institutional review board at each of the
participating centers. All patients gave written informed consent before entering
the study, which was performed in accordance with the Declaration of Helsinki.
Study design and intervention
This was a multicenter randomized (1:1:1) phase 3 clinical trial that involved 58
centers in Italy and 9 centers in the Czech Republic. The primary end point was
PFS; secondary end points included response rate, time to the ﬁrst evidence
of response, OS, and incidence of any grade 3 or higher adverse events.
Per protocol, patients were stratiﬁed by age (75 years or younger vs older than
75 years). On the basis of the recent International Myeloma Working Group
geriatric score that stratiﬁes patients according to their frailty status (ﬁt,
intermediate ﬁtness, and frail),16 a post hoc analysis not prespeciﬁed in the
original protocol was conducted that included age (80 years or younger vs older
than 80years), comorbidities (according toCharlson score), and cognitive and/or
physical status (according to the Activities of Daily Living and the Instrumental
Activities of Daily Living scores). The deﬁnitions of ﬁt, intermediate-ﬁtness,
and frail patients based on age, Charlson score, theActivities ofDaily Living and
the Instrumental Activities of Daily Living scores are summarized in the
supplemental Data available on the Blood Web site.
Patients enrolled were randomly allocated to receive induction treatment
with nine 28-day cycles of MPR (n5 217) or CPR (n5 220) or Rd (n5 217).
First-line dose reductions of dexamethasone, melphalan and cyclophosphamide
were performed according to the patient’s age. MPR patients received
lenalidomide 10mg per day for 21 days, oralmelphalan 0.18mg/kg for 4 days
in patients age 65 to 75 years or 0.13mg/kg in those older than age 75 years, and
prednisone 1.5mg/kg for 4 days. CPRpatients received lenalidomide 10mgper
day for 21 days, oral cyclophosphamide 50 mg every other day for 28 days in
patients age 65 to 75 years or 50 mg every other day for 21 days in those older
than age 75 years, and prednisone 25 mg every other day. Rd patients received
lenalidomide 25mgper day for 21days, dexamethasone 40mgon days 1, 8, 15,
and 22 in patients age 65 to 75 years or 20 mg in those older than age 75 years.
After induction, patients were randomly assigned to receive maintenance
treatment with lenalidomide alone at 10 mg on days 1 to 21 every 28 days or in
combination with prednisone at 25 mg every other day continuously. After the
inclusionof theﬁrst 120patients, theprotocolwasamended to increment thedose
of lenalidomide and cyclophosphamide in patients age 65 to 75 years in the CPR
arm as a result of negligible toxicities compared with the 2 other treatment arms.
The CPR induction schedule was changed to lenalidomide 25 mg per day for
21 days and oral cyclophosphamide 50mg per day for 21 days. All new patients
randomly assigned to the CPR arm received treatment according to the new
regimen after the amendment was approved. Treatment was withheld on with-
drawal of the patient’s consent, disease progression, or the occurrence of any
grade 4 hematologic adverse events or grade 3 to 4 nonhematologic adverse
event; less serious toxicities were managed through established dose-
modiﬁcation guidelines. Antithrombotic prophylaxiswasmandatory: aspirin or
low-molecular-weight heparin or warfarin were permitted at physician’s
discretion.
Assessments of end point
The primary end point was PFS in patients treated with triplet compared with
those who received a doublet combination. PFS was calculated from the time of
induction randomization until the date of progression, relapse, death as a result of
any cause, or the date the patient was last known to be in remission. OS was a
secondary end point in triplet vs doublet regimens and was calculated from the
time of induction randomization until the date of death as a result of any cause or
the date the patient was last known to be alive. Efﬁcacy and safety assessments
were performed every 4 weeks until relapse, or until evidence of disease
progression, or when clinically indicated. Evaluation of the response to the
treatments was performed according to the International Response Criteria
for Multiple Myeloma.17 Adverse events were graded according to the Na-
tional Cancer Institute Common Terminology Criteria for Adverse Events
(version 3.0).
Statistical analysis
The study was designed as a 23 2 factorial trial, with two main comparisons of
PFS: between induction regimens (triplet vs doublet) and between maintenance
treatments (lenalidomide-prednisone vs lenalidomide alone). The design of the
study was to show superiority of a 3-drug regimen over a 2-drug regimen. A
sample size of 640patients (430 in theMPRplusCPRarmsvs 210 in theRdarm)
was determined to provide a power of 80% to detect a PFSHR#0.75 comparing
patients in theMPR and CPR arms with those in the Rd arm by using a log-rank
test with a two-sideda of .05. An interim safety analysis was plannedwhen;85
patients had received at least 1 treatment. Patientswere analyzed on an intention-
to-treat basis for all time-to-event endpoints.Timesofobservationwere censored
on November 1, 2014. Response rates and safety were analyzed in patients who
received at least 1 dose of study drugs. Response rates and the incidence of any
adverse event were compared by using the x2 test or Fisher’s exact test when
appropriate. Survival datawere analyzedbyusing theKaplan-Meiermethod, and
treatment arms were compared with the log-rank test. Time to event was
expressed as median with interquartile range. The Cox proportional hazard
modelwas used to estimateHRvalues and the 95%conﬁdence intervals (CIs) for
the intention-to-treat population.
Results
BetweenAugust 2009 andSeptember 2012, a total of 662 patientswere
enrolled. Eight patients were excluded from randomization for
screening failure (Figure 1). Six hundred ﬁfty-four patients were
randomly assigned to receive induction with MPR (n 5 217) or CPR
(n 5 220) or Rd (n 5 217). Patient baseline and demographic
characteristics werewell balanced among the 3 arms (Table 1).Median
agewas74years in theMPRarm,73years in theCPRarm,and74years
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in theRd arm.About 25%of patientswere classiﬁed as frail.At the time
of analysis, all patients had completed the assigned induction treatment,
and 402 patients were randomly allocated to maintenance treatment.
Themediandurationof treatmentwas18months (range, 1 to62months).
Efficacy
After amedian follow-up of 39months, themedian PFSwas 22months
with triplet and 21months with doublet regimens (HR, 0.906; 95%CI,
0.739-1.111; P5 .344; Figure 2A). The median OS was not reached;
the 4-year OS was 67% with triplet and 58% with doublet regimens
(HR, 0.945; 95%CI, 0.700-1.274;P5 .709; Figure 2B).Bycomparing
the 3 arms separately, the median PFS was 24 months in the MPR,
20 months in the CPR, and 21 months in the Rd arm (Figure 3A). The
4-year OS was 65% with MPR, 68% with CPR, and 58% with Rd
(Figure 3B). After nine induction cycles, the overall response rate (at
least partial response) was similar in the 3 arms: 71% with MPR, 68%
with CPR, and 74% with Rd (Table 2).
A post hoc analysis according to patient frailty was performed
(supplemental Data). By the primary comparison, in ﬁt patients, the
median PFS was 23 months with the triplet regimens and 22 months
with the doublet regimen, and the 4-year OS was 77% and 57%,
respectively. In intermediate-ﬁtness patients, the median PFS was 22
monthswith the triplet and20monthswith the doublet regimen, and the
Figure 1. Patient disposition.
1104 MAGAROTTO et al BLOOD, 3 MARCH 2016 x VOLUME 127, NUMBER 9
For personal use only.on May 18, 2016. by guest  www.bloodjournal.orgFrom 
4-year OSwas 67% and 72%, respectively. In frail patients, themedian
PFS was 18 months with the triplet and 22 months with the doublet
regimen, and the 4-year OS was 44% and 50%, respectively.
When the 3 arms were compared separately, in ﬁt patients, the
median PFS was 30 months in the MPR, 22 months in the CPR, and
22months in theRd arm (MPRvsRd:HR, 0.671; 95%CI, 0.461-0.976;
P5 .037; supplemental Figure panel B). The 4-year OS was 77% in
both MPR and CPR arms and 57% in the Rd arm. In intermediate-
ﬁtness patients, themedianPFSwas 19months in theMPR, 23months
in the CPR, and 20 months in the Rd arm. The 4-year OS was 61% in
the MPR arm and 72% in both the CPR and Rd arms. In frail patients,
themedianPFSwas 23months in theMPR, 14months in theCPR, and
22months in the Rd arm. The 4-yearOSwas 43% in theMPR, 45% in
the CPR, and 50% in the Rd arm.
Safety
During the induction treatment, the most frequent grade$3 toxicities
were hematologic. At least 1 grade$3 hematologic adverse event was
reported in 68% of MPR, 32% of CPR, and 29% of Rd patients
(P , .0001; Table 3). Neutropenic fever occurred in 5 MPR (3%),
4CPR (2%), and 2Rd patients (1%). Per protocol, granulocyte colony-
stimulating factor was administered in case of febrile neutropenia and
grade 3 to 4 neutropenia. In this study, 57% ofMPR, 23% of CPR, and
20% of Rd patients (P , .0001) received granulocyte colony-
stimulating factor, reducing the duration of neutropenia and the risk of
infections. The rate of at least 1 grade $3 nonhematologic adverse
event did not exceed 31% in the 3 arms. The most frequent grade$3
nonhematologic toxicities were infections (11%withMPR, 6.5%with
CPR, and 9% with Rd), constitutional events (9.5% with MPR, 3.5%
with CPR, and 5% with Rd), and cardiac toxicities (4.5% with MPR,
6% with CPR, and 6% with Rd), and no signiﬁcant differences were
detected among the 3 arms (Table 3). A very low incidence of
thromboembolic eventswas recorded: 3% inMPR, 5% inCPR, and2%
in Rd patients. Among the 643 evaluable patients, 203 patients (32%)
received low-molecular-weight heparin, 300 (47%) aspirin, 87 (14%)
both, 16 (2%) warfarin, and 37 (5%) did not receive any prophylaxis.
Table 1. Patient demographic and baseline characteristics
Characteristic
MPR (n 5 218)
No. (%)
CPR (n 5 222)
No. (%)
Rd (n 5 222)
No. (%)
Age, y 63-91 63-87 50-89
Median 74 73 74
.75 86 (39) 80 (36) 83 (37)
Male sex 108 (50) 106 (48) 108 (49)
Karnofsky score 60-100 60-100 60-100
Median 80 90 90
,80 52 (24) 44 (20) 44 (20)
Fitness
Fit 89 (41) 98 (44) 98 (45)
Intermediate fitness 79 (36) 70 (32) 57 (26)
Frail 49 (23) 54 (24) 65 (28)
Data missing 1 (1) 0 2 (1)
Creatinine clearance (mL/min) 30-168 30-152 30-150
Median 70 67 65
International Staging System
score
I 61 (28) 59 (27) 62 (28)
II 97 (45) 103 (46) 99 (45)
III 59 (27) 60 (27) 60 (27)
Missing data 1 (0.5) 0 1 (0.5)
Cytogenetic abnormalities
at FISH
Data available 163 (75) 177 (80) 185 (83)
Data missing 55 (25) 45 (20) 37 (17)
High risk* 38 (17) 48 (22) 47 (25)
FISH, fluorescent in situ hybridization.
*At least one among deletion17p (del17) or translocation (4;14) [t(4;14)] or
translocation (14;16) [t(14;16)].
Figure 2. Kaplan-Meier estimates of PFS and OS in
doublet regimens with no alkylating agents vs
triplet regimens with alkylating agents after a
median follow-up of 39 months. (A) Median PFS
was 21 months in doublet regimens with no alkylating
agents vs 22 months in triplet regimens with alkylating
agents. (B) Four-year OS was 58% in the doublet
regimens with no alkylating agents vs 67% in the triplet
regimens with alkylating agents.
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Grade$3 peripheral neuropathywas not signiﬁcant in any of the arms.
Thirteen cases of second primarymalignancies (SPMs) were recorded:
7 (3%) in theMPR,3 (1%) in theCPR, and3 (1%) inRdarm.Of these, 5
SPMsoccurredduring induction: 3 (1.5%) in theMPRand2 (1%) in the
CPRarm.All SPMswere solid except for 1 case of acute lymphoblastic
leukemia in the CPR arm. Median time to SPM occurrence was
15months (range, 5-36months). The rate of discontinuation as a result
of adverse events was similar in the three arms: 37 (18%) of 211 in the
MPR, 33 (15%) of 220 in the CPR, and 30 (14%) of 212 in the Rd arm.
Lenalidomide was reduced in 45 MPR (21%), 40 CPR (18%), and
34Rdpatients (16%),with no signiﬁcant differences among the 3 arms.
During the induction phase, 27 deaths not related to the progression
of disease occurred: 8 in the MPR (4%), 9 in the CPR (5%), and 10 in
the Rd arm (4%). Nineteen deaths were related to the treatment: 5 in
the MPR (1 sudden death, 3 infections, and 1 stroke), 8 in the
CPR (1 pulmonary embolism, 5 cardiologic toxicities, 1 stroke, and
1 infection), and 6 in the Rd (1 sudden death, 1 decline of general
condition, 1 stroke, and 3 cardiologic toxicities) arm.
In a post hoc analysis, the incidence of at least 1 hematologic
adverse event inﬁt patientswas 75%for thosewho receivedMPR, 34%
for CPR, and 29% for Rd (P5 .0001 for bothMPR vs Rd andMPR vs
CPR). The rate of nonhematologic adverse events was 25% in MPR,
22% in CPR, and 27% in Rd patients. The rate of discontinuation as a
result of adverse events was 13% in patients treated with MPR, 8% in
patients treated with CPR, and 10% in those treated with Rd. Three ﬁt
patients died as a result of treatment-related toxicity (1 per arm). In
intermediate-ﬁtness patients, the incidence of hematologic toxicitywas
61% in MPR, 33% in CPR, and 25% in Rd (MPR vs Rd and MPR vs
CPR,P5 .0001). At least 1 nonhematologic adverse event occurred in
29% ofMPR, 32% of CPR, and 26% of Rd patients. An increased rate
of discontinuation as a result of toxicitieswas detected independentlyof
treatment randomization: 20% with MPR, 13% with CPR, and 18%
with Rd. Two intermediate-ﬁtness patients in the MPR and 2 in the Rd
arm died due to treatment-related toxicities. In frail patients, the
incidence of at least 1 hematologic adverse event was 75%withMPR,
28% with CPR, and 3% with Rd (P5 .0001 for both MPR vs Rd and
MPRvsCPR). The incidence of nonhematologic toxicities was 47% in
MPR, 42% in CPR, and 38% in Rd patients. Frail patients had the
highest rate of discontinuation as a result of adverse events, and thiswas
more evident in the alkylator-containing regimens: 23% with MPR,
30% with CPR, and 18% with Rd. A higher number of frail patients
Figure 3. Kaplan-Meier estimates of PFS and OS
according to treatment arm. (A) Median PFS was 21
months with Rd, 24 months with MPR, and 20 months
with CPR. (B) Four-year OS was 58% with Rd, 65%
with MPR, and 68% with CPR.
Table 2. Response rates
Response
MPR (n 5 211)
No. (%)
CPR (n 5 220)
No. (%)
Rd (n 5 212)
No. (%)
Overall response rate 150 (71) 150 (68) 157 (74)
Complete response 7 (3) 1 (0.5) 6 (3)
Very good partial response 48 (23) 44 (20) 65 (31)
Partial response 95 (45) 105 (48) 86 (41)
Stable disease 51 (24) 62 (28) 49 (23)
Not evaluable* 8 (4) 3 (1) 5 (2)
Progressive disease 2 (1) 5 (2) 1 (0.5)
Median time to response, mo 2 2 1.8
*Patients not evaluable for not completing first induction cycle: Rd: 1 sudden
death, 1 death not specified, 1 heart failure, 1 medical decision, 1 lost at follow-up;
MPR: 4 adverse events (2 fever of unknown origin, 1 not specified, 1 diarrhea and
renal failure), 2 lost at follow-up, 1 death as a result of pneumonia, and 1 sudden
death; CPR: 1 withdrawal of consent, 1 death as a result of sepsis, and 1 death as a
result of atrial fibrillation.
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died due to toxicity: 2 in the MPR (2 infections), 7 in the CPR
(5 cardiologic events, 1 infection, and 1 stroke), and 3 in the Rd
(3 cardiologic events) arm.
Discussion
This is the ﬁrst randomized phase 3 trial that compared two alkylator-
containing triplet regimens (MPR and CPR) with an alkylator-free
doublet regimen (Rd) in patientswithMMwhowere ineligible for stem
cell transplantation. After a median follow-up of 39 months, no
difference in PFS was noticed between triplet and doublet regimens;
thus the hypothesis of the trial has not been conﬁrmed.By analyzing the
3 arms separately, we found that the addition of an alkylating agent did
not lead to any advantage in terms of response and outcome.
In our study, the median PFS with Rd was slightly shorter than that
reported in the FIRST study (25.5monthswith continuousRd and 20.7
months with Rd for 18 months).15 In addition, our response rate was
comparable to the response rate reported in theFIRST trial, inwhich the
overall response ratewithRdwas 73% to75%.However,we reported a
complete response rate of 3% with Rd, which is lower than the 15%
reported in the FIRST trial. Of note, the median duration of continuous
Rd in that trial was 18.4 months, whereas in our study, Rd was
administered for only 9 months as induction treatment followed by
maintenance, which included lenalidomide at a lower dose. Mainte-
nance therapymight have had an impact onPFS, but the current follow-
up does not allow us to draw deﬁnitive conclusions. A future analysis
with a longer follow-up is planned to better evaluate the impact of
maintenance therapy. The more intense regimens of the FIRST study
induced an increase in the extrahematologic toxicity. This suggests that
continuous treatment with Rd can be a valuable option for prolonging
PFS and achieving a deeper response, and reducing the dose during
maintenance can be a valuable strategy for improving tolerability.
In our trial, the major safety concern was the higher hematologic
toxicity reported with MPR compared with that for CPR and Rd
(P, .0001). Nonhematologic adverse events were comparable in the
3 arms, with an incidence not higher than 10%. In the FIRST study, a
higher incidence of infections (29% in continuous Rd, 22% in Rd for
18 months, and 17% in MPT) and cardiac events (12% in continuous
Rd, 7% in Rd for 18 months, and 9% in MPT) was reported.15 This
difference could be the result of longer administration of dexameth-
asone in the FIRST trial compared with our study. A more intensive
induction treatment with Rd administered for a limited duration
(9 months) followed by a less intensive continuous treatment with
lenalidomide alone seems to be a sensible and effective choice.
In our trial, the incidence of SPM (2%)was not higher than the rates
reported in other studies with lenalidomide-containing regimens. Of note,
the incidence was higher with the alkylator-containing regimens, with
3casesofSPMreported in theRdarmversus10cases in theMPRandCPR
arms. This is in line with a previous meta-analysis that demonstrated an
increased riskofSPMwith lenalidomide in combinationwithmelphalan.18
Cyclophosphamide was shown to be less toxic and was associated
with a lower risk of SPM thanmelphalan, and thusmay be considered an
alternative.18,19Nevertheless,wefoundnoparticular advantage in termsof
efﬁcacy with CPR over the 2-drug Rd regimen. Despite the amendment,
we might have adopted a dose of cyclophosphamide that was too low in
our study. Because of this limitation, no deﬁnitive conclusions can be
drawn regarding CPR. To date, in the elderly setting, 1 phase 2 trial has
evaluated cyclophosphamide300mg/m2 in combinationwith carﬁlzomib
anddexamethasonewith positive results.19Thismayprovide the rationale
for also testing this dose in lenalidomide-containing regimens.
Determining treatment doses based only on age could be a limit.
Therefore, we conducted a post hoc analysis and classiﬁed patients as
ﬁt, intermediateﬁtness, and frail.16With all the limitations of a post hoc
analysis, we found a PFS advantage with MPR compared with Rd
(HR, 0.671;P5 .037) and CPR in ﬁt patients. Intermediate-ﬁtness and
frail patients did not beneﬁt from the addition of an alkylating agent.
Hematologic toxicities were similar in ﬁt, intermediate-ﬁtness, and frail
patients within each treatment arm. MPR was conﬁrmed to be the
combination with the highest incidence of hematologic adverse events,
independently of the patients’ frailty status. Conversely, frailty in-
ﬂuenced the risk of nonhematologic toxicities, discontinuation, and
treatment-related deaths. In frail patients in theMPR arm, infectionwas
the only cause of death, thus reﬂecting the marked immune depression
with this combination; in frail patients in the CPR and Rd arms,
cardiovascular toxicity was the major cause of death, and this is in line
with the toxicity proﬁle of the 2 combinations. Nevertheless, caution is
necessary when interpreting these data because the frailty analysis was
not prespeciﬁed; thus, no deﬁnitive conclusions can be drawn. Future
studies that include frailty evaluation may validate our results. In real
life, a simple geriatric evaluation in the outpatient setting can be
performed and may be a valuable tool to guide clinicians in the
treatment decision process.
In conclusion, this trial showed that in real-life elderly myeloma
patients, the alkylator-containing MPR or CPR triplet regimens were
Table 3. Grade ‡3 adverse events during induction treatment
Grade ‡3 adverse event
MPR (n 5 211)
No. (%)
CPR (n 5 220)
No. (%)
Rd (n 5 212)
No. (%)
Hematologic
At least one event 143 (68) 71 (32) 61 (29)
Anemia 32 (15) 14 (6) 9 (4)
Neutropenia* 136 (64) 63 (29) 52 (25)
Thrombocytopenia 37 (18) 19 (9) 15 (7)
Nonhematologic
At least one event 66 (31) 66 (30) 63 (30)
Cardiologic 9 (4.5) 11 (6) 13 (6)
Arrythmia 2 (1) 2(1) 3 (1.5)
Acute myocardial infarction 1 (0.5) 4(2) 4 (2)
Heart failure 2(1) 3(1.5) 4 (2)
Other 4(2) 2(1) 2 (1)
Vascular 7 (3.5) 12 (5) 7 (3)
Deep vein thrombosis/
thromboembolism
6 (3) 10 (5) 5 (2)
Stroke 1 (0.5) 2 (1) 2 (1)
Constitutional 19 (9.5) 7 (3.5) 11 (5)
Fever 10 (5) 2 (1) 3 (1.5)
Fatigue 6 (3) 4(2) 5(2)
Other 3 (1.5) 1(0.5) 3(1.5)
Dermatologic 9 (5) 17 (8) 11 (5)
Infection 23 (11) 16 (6.5) 20 (9)
Pneumonia 2 (1) 6(2.5) 4(2)
Bronchitis 1 (0.5) 0 3 (1.5)
Sepsis 2 (1) 2 (1) 2 (1)
Enteritis 0 2 (1) 2 (1)
Febrile neutropenia 8 (4) 4 (2) 3 (1.5)
Viral reactivation 6 (2) 0 1 (0.5)
Other/not specified 4 (1) 2 (1) 5 (1)
Peripheral neurolopathy 6 (3) 6 (3) 5 (2)
Second primary malignancies 3 (1.5) 2 (1) 0
Hematologic 0 1 (0.5) 0
Solid 3 (1.5) 1 (0.5) 0
Discontinuation due to adverse
events
37 (18) 33 (15) 30 (14)
*Administration of granulocyte colony-stimulating factor: Rd, 43 (20%); MPR,
120 (57%); CPR, 51 (23%).
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not superior to the alkylator-free Rd doublet. This is in line with the
registrational FIRST study, in which Rd was demonstrated to be
effective for all elderly patients.15
In this era of novel effective drugs, new attractive therapeutic
options are now available, and Rd should be optimized through the
addition of novel agents. Recently, the addition of carﬁlzomib to Rd
was shown tobe effective in the relapsed setting,20 and results of aphase
1/2 trial demonstrated that this combination is well tolerated and is also
effective in newly diagnosed patients.21Monoclonal antibodies such as
elotuzumab were shown to be effective in combination with Rd in the
relapsed setting, and further investigation in the newly diagnosed
setting is needed.22 In the future, trials will conﬁrm the role of novel
agents in this setting, and these agents may increase the treatment
armamentarium against myeloma.
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